Molecular Diagnosis & Therapy

, Volume 23, Issue 6, pp 811–812 | Cite as

Comment on “Prognostic Significance of FOXC1 in Various Cancers: A Systematic Review and Meta-Analysis”

  • Bolin Wang
  • Yan HuangEmail author
Letter to the Editor


Compliance with Ethical Standards


No sources of funding were used to conduct this study or prepare this letter.

Conflict of interest

Bolin Wang and Yan Huang have no conflicts of interest have no conflicts of interest that are directly relevant to the content of this letter.


  1. 1.
    Sabapathi N, Sabarimurugan S, Madurantakam Royam M, Kumarasamy C, Xu X, Xu G, et al. Prognostic significance of FOXC1 in various cancers: a systematic review and meta-analysis. Mol Diagn Ther. 2019. Scholar
  2. 2.
    Huang L, Huang Z, Fan Y, He L, Ye M, Shi K, et al. FOXC1 promotes proliferation and epithelial-mesenchymal transition in cervical carcinoma through the PI3K-AKT signal pathway. Am J Transl Res. 2017;9(3):1297–306.PubMedPubMedCentralGoogle Scholar
  3. 3.
    Xu YL, Yao R, Li J, Zhou YD, Mao F, Pan B, et al. FOXC1 overexpression is a marker of poor response to anthracycline-based adjuvant chemotherapy in sporadic triple-negative breast cancer. Cancer Chemother Pharmacol. 2017;79(6):1205–13.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Weifang Medical UniversityWeifangPeople’s Republic of China
  2. 2.Department of OncologyAffiliated Hospital of Weifang Medical UniversityWeifangChina

Personalised recommendations